US20030166610A1 - Nutritional composition - Google Patents

Nutritional composition Download PDF

Info

Publication number
US20030166610A1
US20030166610A1 US10/350,092 US35009203A US2003166610A1 US 20030166610 A1 US20030166610 A1 US 20030166610A1 US 35009203 A US35009203 A US 35009203A US 2003166610 A1 US2003166610 A1 US 2003166610A1
Authority
US
United States
Prior art keywords
carbohydrate
nutritional composition
composition
carbohydrates
nutritional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/350,092
Other languages
English (en)
Inventor
Florence Rochat
Olivier Ballevre
Alfred Jann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BALLEVRE, OLIVIER, JANN, ALFRED, ROCHAT, FLORENCE
Publication of US20030166610A1 publication Critical patent/US20030166610A1/en
Priority to US10/942,722 priority Critical patent/US7141554B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Definitions

  • the present invention relates to a nutritional composition which comprises synergistic functional carbohydrates for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health; a method of production of the composition; and a method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an effective amount of the composition.
  • the present invention provides a nutritional composition for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises at least two synergistic functional carbohydrates wherein a first carbohydrate is selected from the group which consists of inulin or fructooligosaccharide (FOS), and a second carbohydrate is selected from the group which consists of xylooligosaccharide (XOS), acacia gum and resistant starch.
  • the carbohydrates may be obtained commercially or more simply by the use of a natural source (e.g., chicory as source of inulin).
  • the invention provides a method of production of the composition which comprises blending the first and second carbohydrates in required amounts.
  • the invention provides a method of treating an infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an amount of the nutritional composition effective to stimulate intestinal bifidobacteria, and thus promote associated health benefits, according to an embodiment of the invention.
  • the invention provides a method to reduce side effects of the consumption of fiber, which comprises administering fiber in form of the composition according to the invention.
  • the present invention provides a method to reduce the symptoms of the Irritable Bowel Syndrome (IBS), which comprises administrating an amount of the composition effective to stimulate intestinal bifidobacteria, and thus prevent or treat the IBS, according to the invention.
  • IBS Irritable Bowel Syndrome
  • FIG. 1 shows the effect of various carbohydrates or blends thereof on fecal bifidobacteria in human.
  • side effects is taken to mean undesirable effects often occurring after consumption of fiber. These side effects include, for example, flatulences, bloating and intestinal pain.
  • the bifidobacteria population is not the same from one individual to another and often comprises several different species of bifidobacteria.
  • the bifidobacteria enzymes implicated in the fermentation of embodiments of a composition according to the present invention are not identical depending on the physical and chemical structures of the carbohydrates.
  • the bifidobacteria are not similar with regard to their enzymatic capacity, e.g., the ability to ferment one fiber or another.
  • a nutritional composition according to the invention which comprises a mixture of two carbohydrates or more promotes the growth of more bifidobacteria species than a single carbohydrate does.
  • carbohydrates examples of which include: fructooligosaccharides, galacto-oligosaccharide, soybean-gum, gum, starch
  • one embodiment of the nutritional composition according to the present invention comprises fructooligosaccharide and a carbohydrate selected from the group which consists of xylooligosaccharide and acacia gum. More preferably, it comprises fructooligosaccharide and acacia gum.
  • Another embodiment of the nutritional composition according to the present invention comprises about 1 g to about 20 g of a first carbohydrate and about 0.1 to about 20 g of a second carbohydrate. More preferably, it comprises about 1 g to about 3 g of a first carbohydrate and about 0.2 g to about 3 g of a second carbohydrate for an infant, and about 2 g to about 5 g of a first carbohydrate and about 2 g to about 5 g of a second carbohydrate for an adult, although it will be apparent that there are no specific limitations except for what can reasonably be consumed and the price.
  • the amounts given correspond to a daily dose, which may be divided into several servings in one day, if desired.
  • a ratio by weight of the first and the second functional carbohydrate is 1-20:0.1-20. More preferably, it is between 0.05-10:1,even more preferably, between 0.1-10:1.
  • the invention also provides an edible composition formulated for human consumption and/or administration.
  • This composition includes a food, food-forming, beverage, or beverage-forming component and one of the nutritional compositions of the invention.
  • An alternative embodiment of this edible composition is formulated for consumption by a companion animal.
  • One advantage of the present invention is that it provides a composition that can be provided in a functional food product and which therefore does not require special administration.
  • Another advantage of the present invention is that it does not adversely kill or affect non-harmful intestinal bacteria.
  • Yet another advantage of the present invention is that it provides a decrease of the daily amount of carbohydrates required in the gut to obtain stimulation of intestinal bifidobacteria and for the promotion of the associated health benefits.
  • the benefits that this decrease provides include reduction of the side effects (abdominal disturbance) induced by the intake of some fermentable carbohydrates, and in some cases a reduction in cost.
  • Yet another advantage of the present invention is that it provides a composition of carbohydrates having various lengths of carbohydrate chains. This enables modulating fermentation throughout the colon as the composition passes through it.
  • a nutritional composition preferably comprises a source of protein.
  • Dietary protein is preferred as a source of protein.
  • the dietary protein may be any suitable dietary protein, for example an animal protein (such as milk protein, meat protein or egg protein); a vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
  • the composition may also comprise a source of fat.
  • the fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; more preferably about 20% to about 50% of the energy.
  • Lipids making up the fat source may be any suitable fat or fat mixture. Vegetable fat is particularly suitable, for example, soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithins, and the like. Animal fat such as milk fat may also be added if desired.
  • An additional source of carbohydrate may be added to the nutritional composition. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable carbohydrate may be used, for example, sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, or a mixture thereof.
  • Additional dietary fiber may also be added if desired. If added, it preferably comprises up to about 5% of the energy of the nutritional composition.
  • the dietary fiber may be from any suitable origin, including, for example, soy, pea, oat, pectin, guar gum, acacia gum, fructooligosaccharide or a mixture thereof.
  • Suitable vitamins and minerals may be included in the nutritional composition in an amount to meet the appropriate guidelines.
  • One or more food grade emulsifiers may be included in the nutritional composition if desired, for example, diacetyl tartaric acid esters of mono- and di-glycerides, lecithin and mono- or di-glycerides or a mixture thereof. Similarly, suitable salts and/or stabilizers may be included.
  • the nutritional composition is preferably enterally administrable, for example, in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a common food product may be enriched with an embodiment of the composition.
  • a milk such as a fermented milk, a yogurt, a fresh cheese, or a renneted milk
  • the food product may also be a confectionery bar, breakfast cereal flakes or bars, a drink, milk powder, soy-based product, non-milk fermented product or a nutritional supplement for clinical nutrition, infant formulae or baby food.
  • the amount of the composition added is preferably at least about 0.01% by weight.
  • composition may be included in an article of confectionery, for example a sweet or sweetened beverage.
  • FOS 6 g daily of (Raftilose P95N) during 6 weeks.
  • XOS 0.4 g daily of Xylo-oligo P95 during 6 weeks
  • XOS FOS 4 g daily of FOS and 0.2 g daily of XOS, during 6 weeks
  • FOS 200 ml of skimmed milk with Raftilose P95®, 6 g per serving.
  • Fibergum 200 ml of skimmed milk with Fibergum AS IRX®, 6 g per serving.
  • FOS+Fibergum 200 ml of skimmed milk with Raftilose P95® (3 g per serving) and Fibergum TX® (3 g per serving).
  • the intervention period is between day 21 and 49.
  • the change from day 21 to day 28 is of particular interest.
  • the “responders” were determined with the criteria of an increase of at least +0.5 log 10 cfu/g of faeces. This was observed for 13 out of 29 subjects, which represented 44.8% of the volunteers. A 95%-confidence interval for this proportion was from 27 to 64%. We could say that at least 27% of the subjects responded to the diet provided, and it could be as high as 64%.
  • the primary analysis as to the outcome is the effect on the amount of Bifidobacteria in the feces. Counts of other micro-organisms were also analyzed. A further analysis was carried out to determine changes of abdominal sensation (flatulencies, quality and number of stools) as assessed by the volunteers, followed by an analysis of several short chain fatty acids measured in the feces.
  • Control 13 subjects (8 females, 5 males)
  • FOS + GUM 29 subjects (19 females, 10 males)
  • Starch 29 subjects (19 females, 10 males)
  • Blend 29 subjects (19 females, 10 males)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Grain Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
US10/350,092 2000-07-24 2003-01-24 Nutritional composition Abandoned US20030166610A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/942,722 US7141554B2 (en) 2000-07-24 2004-09-16 Method of treating irritable bowel syndrome

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00115850.0 2000-07-24
EP00115850A EP1175905A1 (en) 2000-07-24 2000-07-24 Nutritional Composition
PCT/EP2001/008283 WO2002007533A2 (en) 2000-07-24 2001-07-17 Nutritional composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008283 Continuation WO2002007533A2 (en) 2000-07-24 2001-07-17 Nutritional composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/942,722 Division US7141554B2 (en) 2000-07-24 2004-09-16 Method of treating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
US20030166610A1 true US20030166610A1 (en) 2003-09-04

Family

ID=8169332

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/350,092 Abandoned US20030166610A1 (en) 2000-07-24 2003-01-24 Nutritional composition
US10/942,722 Expired - Lifetime US7141554B2 (en) 2000-07-24 2004-09-16 Method of treating irritable bowel syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/942,722 Expired - Lifetime US7141554B2 (en) 2000-07-24 2004-09-16 Method of treating irritable bowel syndrome

Country Status (22)

Country Link
US (2) US20030166610A1 (es)
EP (4) EP1175905A1 (es)
JP (1) JP4955896B2 (es)
KR (1) KR20030041962A (es)
CN (1) CN100349575C (es)
AT (1) ATE485827T1 (es)
AU (1) AU2001289680A1 (es)
BG (1) BG107473A (es)
BR (2) BRPI0112685B1 (es)
CA (1) CA2416990C (es)
CZ (1) CZ2003535A3 (es)
DE (1) DE60143356D1 (es)
DK (1) DK1305036T3 (es)
ES (2) ES2650122T3 (es)
HU (1) HUP0303728A3 (es)
IL (1) IL153989A (es)
MX (1) MXPA03000742A (es)
NO (1) NO20030316L (es)
PL (1) PL366049A1 (es)
PT (1) PT1305036E (es)
WO (1) WO2002007533A2 (es)
ZA (1) ZA200301401B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104760A1 (en) * 2003-12-12 2007-05-10 Takeo Yokawa Enteropathy ameliorating composition
US20100166916A1 (en) * 2005-11-30 2010-07-01 Sis (Science In Sport) Limited Nutritional products
RU2543662C2 (ru) * 2003-10-24 2015-03-10 Н.В. Нютрисиа Синбиотическая композиция для детей для профилактики или лечения раздражения кожи от пеленок
CN115997932A (zh) * 2021-10-22 2023-04-25 马斯公司 用作食物组合物的核苷酸和低聚糖

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815824B1 (fr) * 2000-10-31 2003-04-25 Colloides Naturels Internat Methode et preparation de type fibre alimentaire soluble bifidogene pour la mise en oeuvre de ladite methode
AU2002331469B2 (en) 2001-08-20 2008-04-24 Cargill, Incorporated Non-starch-polysaccharides
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
FR2848783B1 (fr) * 2002-12-18 2005-05-13 Agronomique Inst Nat Rech Utilisation de prebiotiques pour prevenir ou traiter le stress oxydant
RU2362560C2 (ru) 2003-04-08 2009-07-27 Проджиникс Фармасьютикалз, Инк. Фармацевтическая препаративная форма
NO320546B1 (no) * 2003-12-12 2005-12-19 Nova Biotics As Prebiotiske kombinasjonsprodukter
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
WO2006091103A2 (en) * 2005-02-28 2006-08-31 N.V. Nutricia Nutritional composition with probiotics
AU2006220682B2 (en) 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2682550C (en) 2007-03-29 2016-05-17 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100305323A1 (en) 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
GB0718974D0 (en) 2007-09-28 2007-11-07 Univ Leuven Kath oligosaccharides derived from arabinoxylan for prevention of gastrointestinal infection
ES2611203T3 (es) * 2007-12-21 2017-05-05 N.V. Nutricia Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
GB0805360D0 (en) 2008-03-25 2008-04-30 Univ Leuven Kath Arabinoxylan oligosaccharide preparation
MX337272B (es) 2008-03-28 2015-10-06 Nestec Sa Probioticos para usarse en mamiferos hembra preñadas para incrementar la inmunidad de sus crias.
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN107320480A (zh) 2009-02-24 2017-11-07 里特制药股份有限公司 益生素制剂和使用方法
DK2498626T3 (en) 2009-11-12 2015-07-13 Nestec Sa FOOD COMPOSITION TO PROMOTE GAS MICROFLORAL BALANCE AND HEALTH
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
KR101421807B1 (ko) * 2012-09-28 2014-07-22 주식회사 포스코 코크스 오븐의 타르 제거장치
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
CN103704472B (zh) * 2013-12-13 2016-03-23 山东星光生物科技有限公司 一种低聚果糖功能性浓缩饲料及其制备方法
AU2014369772A1 (en) 2013-12-20 2016-05-19 Nestec S.A. Nutritional compositions for reducing intestinal pathogens
CN104920809B (zh) * 2014-03-18 2018-02-23 中国科学院大连化学物理研究所 一种改善母猪***中乳汁寡糖的饲料添加剂预混剂及其使用方法
US20170056462A1 (en) * 2014-04-25 2017-03-02 Nexira International Use of a composition comprising arabic gum (ag) for improving gut impermeability
JP6688736B2 (ja) * 2014-10-03 2020-04-28 株式会社明治 オリゴ糖製剤及びその製造方法
CN104939082A (zh) * 2015-06-02 2015-09-30 西安膳方医药科技有限公司 一种复合益生元及其制备方法
EA035945B1 (ru) * 2015-08-04 2020-09-04 Зюдцукер АГ Профилактическое использование инулина от синусита
CA2995347A1 (en) * 2015-08-11 2017-02-16 Shaklee Corporation Materials and methods for improving gastrointestinal health
KR20190105055A (ko) * 2017-01-13 2019-09-11 액세스 비지니스 그룹 인터내셔날 엘엘씨 전분분해 및 단쇄 지방산 생산 미생물의 활성을 촉진하기 위한 식이성 프리바이오틱 보충제
CN108902970A (zh) * 2018-06-27 2018-11-30 安徽瑞康食品生物科技有限公司 含有戊聚糖的食用组合物，功能食品及其制备方法、用途
CN109315728A (zh) * 2018-09-19 2019-02-12 北京爱仁医疗科技有限公司 一种含有虾青素的食品及其在肠道菌群调节中的应用
WO2022083858A1 (en) * 2020-10-21 2022-04-28 Compagnie Gervais Danone Acacia gum for iron induced microbial dysbiosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
US5792754A (en) * 1995-08-04 1998-08-11 N.V. Nutricia Nutritional composition containing fibres
US6197361B1 (en) * 1996-12-24 2001-03-06 Nestec S.A. Gelatinized cereal product containing oligosaccharide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827526A (en) * 1995-07-11 1998-10-27 Abbott Laboratories Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans
US5721004A (en) * 1996-03-01 1998-02-24 Kraft Foods, Inc. Method for producing fat-free and low-fat viscous dressings using inulin
IT1304170B1 (it) * 1998-12-15 2001-03-08 Novartis Nutrition Ag Composti organici
JP4273277B2 (ja) * 1999-06-30 2009-06-03 大塚製薬株式会社 オリゴ糖補給組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
US5792754A (en) * 1995-08-04 1998-08-11 N.V. Nutricia Nutritional composition containing fibres
US6197361B1 (en) * 1996-12-24 2001-03-06 Nestec S.A. Gelatinized cereal product containing oligosaccharide

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2543662C2 (ru) * 2003-10-24 2015-03-10 Н.В. Нютрисиа Синбиотическая композиция для детей для профилактики или лечения раздражения кожи от пеленок
US20070104760A1 (en) * 2003-12-12 2007-05-10 Takeo Yokawa Enteropathy ameliorating composition
US8148351B2 (en) 2003-12-12 2012-04-03 Taiyo Kagaku Co., Ltd. Enteropathy ameliorating composition
US20100166916A1 (en) * 2005-11-30 2010-07-01 Sis (Science In Sport) Limited Nutritional products
CN115997932A (zh) * 2021-10-22 2023-04-25 马斯公司 用作食物组合物的核苷酸和低聚糖

Also Published As

Publication number Publication date
JP2004504332A (ja) 2004-02-12
ES2650122T3 (es) 2018-01-17
EP1305036A2 (en) 2003-05-02
AU2001289680A1 (en) 2002-02-05
NO20030316D0 (no) 2003-01-21
EP2204176A2 (en) 2010-07-07
US7141554B2 (en) 2006-11-28
BRPI0112685B1 (pt) 2020-04-07
EP1305036B1 (en) 2010-10-27
MXPA03000742A (es) 2003-09-25
BG107473A (bg) 2004-07-30
EP1175905A1 (en) 2002-01-30
EP2204176A3 (en) 2010-07-14
CA2416990C (en) 2010-09-14
KR20030041962A (ko) 2003-05-27
DK1305036T3 (da) 2011-02-07
ATE485827T1 (de) 2010-11-15
IL153989A0 (en) 2003-07-31
HUP0303728A3 (en) 2004-12-28
BR0112685A (pt) 2003-06-24
WO2002007533A2 (en) 2002-01-31
EP2255815B1 (en) 2017-10-25
ES2355754T3 (es) 2011-03-30
PL366049A1 (en) 2005-01-24
DE60143356D1 (de) 2010-12-09
CN100349575C (zh) 2007-11-21
HUP0303728A2 (hu) 2004-03-29
CZ2003535A3 (cs) 2003-09-17
PT1305036E (pt) 2011-01-28
EP2255815A3 (en) 2012-07-11
WO2002007533A3 (en) 2002-04-11
EP2255815A2 (en) 2010-12-01
JP4955896B2 (ja) 2012-06-20
ZA200301401B (en) 2004-05-21
CA2416990A1 (en) 2002-01-31
US20050053641A1 (en) 2005-03-10
NO20030316L (no) 2003-03-14
CN1466459A (zh) 2004-01-07
IL153989A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
US7141554B2 (en) Method of treating irritable bowel syndrome
US6207638B1 (en) Nutritional intervention composition for enhancing and extending satiety
JP4793533B2 (ja) ポリデキストロースでの免疫系の刺激
US7101553B2 (en) Immune response enhancement methods
EA006441B1 (ru) Способ и композиция для уменьшения воспалительного процесса и/или аномальной активации неспецифической иммунной реакции
US20070020249A1 (en) Compositions for prevention and treatement of symptoms of gastrointestinal distress
US20150044326A1 (en) Composition comprising a mixture of fibers
US20160089392A1 (en) Whey Protein and Resistant Starch Compositions to Reduce Body Mass Index
JPS62220169A (ja) 流動性食品
KR100787554B1 (ko) 혈중 저분자량질소함유화합물의 농도 저감용 식품
KR20060127874A (ko) 장질환 개선용 조성물
RU2096974C1 (ru) Способ коррекции углеводного состава пищевых продуктов общего и специального назначения (варианты)
EP3431093A1 (en) Wheat-derived polysaccharides for reduction of antibiotic resistance
RU2556909C1 (ru) Способ получения концентрата на основе бад для напитка (варианты), рецептура концентрата для напитка быстрого приготовления, способ приготовления и способ применения напитка, полученного из этого концентрата
Nielsen Evaluation of whey permeate in the treatment of moderate malnutrition

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROCHAT, FLORENCE;BALLEVRE, OLIVIER;JANN, ALFRED;REEL/FRAME:014044/0861;SIGNING DATES FROM 20030129 TO 20030210

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION